A GSK-led consortium looks to break ground with a new class of antibiotic, pushing into a pivotal
After watching a slew of biotechs crash and burn after fielding a lineup of freshly approved antibiotics, GlaxoSmithKline is hoping to achieve something new in the field. The pharma giant, backed by some big public partners, has commenced the first of two large Phase III large clinical trials for an experimental antibiotic gepotidacin, targeting 2 infections that haven’t seen a new oral antibiotic in more than 20 years.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.